EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Updates on Pharmacologic Management of Microvascular Angina

Mosayeb Soleymani, Farzad Masoudkabir iD, Mahsima Shabani iD, Ali Vasheghani-Farahani iD, Amir Hossein Behnoush iD, Amirmohammad Khalaji iD

Cardiovascular Therapeutics · 25.10.2022 · 2022 · 1-19

DOI: 10.1155/2022/6080258 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, erschienen am 25.10.2022. Verfasst von Mosayeb Soleymani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Microvascular Angina, Coronary Artery Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 208 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microvascular angina (MVA), historically called cardiac syndrome X, refers to angina with nonobstructive coronary artery disease. This female-predominant cardiovascular disorder adds considerable health-related costs due to repeated diagnostic angiography and frequent hospital admissions. Despite the high prevalence of this diagnosis in patients undergoing coronary angiography, it is still a therapeutic challenge for cardiologists. Unlike obstructive coronary artery disease, with multiple evidence-based therapies and management guidelines, little is known regarding the management of MVA. During the last decade, many therapeutic interventions have been suggested for the treatment of MVA. However, there is a lack of summarization tab and update of current knowledge about pharmacologic management of MVA, mostly due to unclear pathophysiology. In this article, we have reviewed the underlying mechanisms of MVA and the outcomes of various medications in patients with this disease. Contrary to vasospastic angina in which normal angiogram is observed as well, nitrates are not effective in the treatment of MVA. Beta-blockers and calcium channel blockers have the strongest evidence of improving the symptoms. Moreover, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, statins, estrogen, and novel antianginal drugs has had promising outcomes. Investigations are still ongoing for vitamin D, omega-3, incretins, and n-acetyl cysteine, which have resulted in beneficial initial outcomes. We believe that the employment of the available results and results of the future large-scale trials into cardiac care guidelines would help reduce the global cost of cardiac care tremendously.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Microvascular AnginaCoronary Artery DiseaseHumansFemaleCoronary AngiographyAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme Inhibitors

Substanzen

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme Inhibitors

Autor:innen und Institutionen

  • Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Cardiac Electrophysiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Division of Cardiology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
  • Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Farzad Masoudkabir, Mahsima Shabani, Ali Vasheghani-Farahani, Amir Hossein Behnoush, Amirmohammad Khalaji

Zitieren

APA

Soleymani, M., Masoudkabir, F., Shabani, M., Vasheghani-Farahani, A., Behnoush, A. H., & Khalaji, A. (2022). Updates on Pharmacologic Management of Microvascular Angina. Cardiovascular Therapeutics, 2022, 1-19. https://doi.org/10.1155/2022/6080258

Vancouver

Soleymani M, Masoudkabir F, Shabani M, Vasheghani-Farahani A, Behnoush AH, Khalaji A. Updates on Pharmacologic Management of Microvascular Angina. Cardiovascular Therapeutics. 2022;2022:1-19. doi:10.1155/2022/6080258

BibTeX
@article{Soleymani2022,
  author = {Soleymani, Mosayeb and Masoudkabir, Farzad and Shabani, Mahsima and Vasheghani-Farahani, Ali and Behnoush, Amir Hossein and Khalaji, Amirmohammad},
  title = {Updates on Pharmacologic Management of Microvascular Angina},
  journal = {Cardiovascular Therapeutics},
  year = {2022},
  volume = {2022},
  pages = {1--19},
  doi = {10.1155/2022/6080258}
}
Kostenlos starten →